Skip to main
IFRX
IFRX logo

InflaRx (IFRX) Stock Forecast & Price Target

InflaRx (IFRX) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

InflaRx NV is a clinical-stage biopharmaceutical company developing vilobelimab, a first-in-class anti-C5a monoclonal antibody that has shown a significant reduction in all-cause mortality by 23.9% within 28 days of treatment. The therapy has also demonstrated the potential to lower corticosteroid use, promoting corticosteroid-free treatment options for patients with autoimmune vasculitis (AAV). These promising clinical results underscore the potential market opportunity for vilobelimab in managing inflammatory diseases, signaling a positive outlook for the company's stock.

Bears say

InflaRx NV is facing a negative outlook largely due to its depressed forward multiples, which are attributed to ongoing market volatility. The company's cash burn is uncertain and could be significantly influenced by the developmental stage of its programs, as well as by potential revenue influx from partnerships or collaborations. Additionally, the commercial sales of GOHIBIC are not currently valued, as the asset is not considered to be in a growth stage, with projected revenue generation remaining stagnant.

InflaRx (IFRX) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InflaRx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InflaRx (IFRX) Forecast

Analysts have given InflaRx (IFRX) a Buy based on their latest research and market trends.

According to 5 analysts, InflaRx (IFRX) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InflaRx (IFRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.